The DOI matches its Crossref record; 18 of the 20 references it cites were found in a registry or an index; 20 of the 35 sources its claims cite were checked for support.
HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey
Open accessAbstract
The optimal hormone replacement therapy (HRT) in women who have undergone pelvic clearance for endometriosis remains uncertain with insufficient evidence. The purpose of this case report and the national survey was to highlight the potential HRT-related risks and to establish current HRT practice in this group of women. The case was a 45-year-old woman presenting with recurrence of severe chronic pelvic pain while on oestrogen-only HRT (EO-HRT) for five years after subtotal hysterectomy and bilateral oophorectomy for severe endometriosis. MRI revealed multiple peri-cervical endometriomas and severe right hydroureter/hydronephrosis with complete right renal parenchymal loss. The survey was a 21-item questionnaire administered electronically using SurveyMonkey. It was reviewed and approved by British Menopause Society and British Society of Gynaecological endoscopy and was sent to their members as well as NHS Gynaecologists. A total of 216 physicians responded including 120 (55.6%) Gynaecology Consultants and 96 (44.4%) GPs/Nurses in Menopause clinics. Overall, 68.6% of responders prescribe combined HRT (C-HRT), 11.1% tibolone, 13.0% EO-HRT and 7.8% varied HRT. Fifty-one percent prescribe the progestogen component of C-HRT indefinitely, 22% for 3–6 months and 27% for varied durations. In conclusion, this study highlights the real risk of endometriosis recurrence in EO-HRT users after pelvic clearance for endometriosis. The survey revealed that only two thirds of Gynecologists/Menopause practitioners prescribe combined HRT in this group of women.
Overview
CoChat Summary
TL;DR
This paper combines a case report and a UK national survey on hormone replacement therapy (HRT) after pelvic clearance for endometriosis. It reports severe endometriosis recurrence with oestrogen-only HRT and wide variation in clinician practice, with only about two-thirds prescribing combined HRT.
Key findings
- In the case report, a 45-year-old woman developed recurrence of severe chronic pelvic pain while on high-dose oestrogen-only HRT (estradiol valerate 3 mg/day) five years after subtotal hysterectomy and bilateral salpingo-oophorectomy for severe endometriosis; MRI showed multiple peri-cervical endometriomas (largest 3 cm), severe right hydroureter/hydronephrosis, and complete right renal parenchymal loss. After trachelectomy and excision of endometriomas, she reported complete disappearance of pelvic pain six weeks after surgery.
- In the national survey, 216 clinicians responded (70% completion rate). Overall, 68.6% prescribe combined HRT, 13.0% oestrogen-only HRT, 11.1% Tibolone, and 7.8% varied HRT.
- Most responders (63.4%) start HRT immediately after surgery; 60.9% would give the progestogen component indefinitely, while 19.3% would give it for 1–2 years and 8.5% for 3–6 months.
- Most responders offer combined HRT to prevent recurrence of endometriosis (79%), de novo endometriosis (39%), or malignant transformation of residual endometriosis (42%); 63% prescribe combined HRT based on anecdotal evidence and personal experience, and 66% indicated a lack of clear guidance.
Methods
- Design: a case report plus a cross-sectional national survey of clinicians managing surgical menopause after pelvic clearance for endometriosis, defined as total hysterectomy and bilateral salpingo-oophorectomy with excision of endometriosis.
- Survey: a 21-item electronic questionnaire administered via SurveyMonkey, reviewed and approved by representatives of the British Menopause Society and British Society of Gynaecological Endoscopy, and sent to their members and other NHS gynaecologists; 216 responses were analysed after excluding one irrelevant responder.
- Analysis: descriptive percentages are reported, with comparison between responder grades using a Q-square test; a statistically significant difference (<0.05) was found between gynaecology consultants and GP/CNS/APN in prescribing Tibolone (25.0% versus 2.3%).
Limitations
- The paper states that the survey relied on self-reporting of practice with no independent verification of actual management, and that presenting a list of “ideal” options may have resulted in respondent bias.
- The paper states that responder numbers in each group were not as large as hoped, though they were considered a very good representative sample, and the 70% completion rate was considered excellent for this type of survey.
- Evident from the text: the case report is a single patient, which limits generalizability; the paper also notes limited evidence and calls for adequately powered prospective studies.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures





Verification
Claims the paper makes
17 Valid · 2 Not valid · 7 Not checked · 68 Own results and interpretations
At least one cited source doesn’t support this claim or points to a different paper, and none confirmed it — see the verdicts below.
In the paper
“Notably, seven of these 14 reported cases had extensive or severe endometriosis.”
§ HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey > 4. Discussion > 4.1. Results in the Light of Previous Research
What the sources say
- Disputedcites [8] Gemmell, 2017, The management of menopause in women with a history of endometriosis: A systematic review, Hum. Reprod. Update sourceExperimental — accuracy not yet measured
In Results, under “Endometriosis recurrence in women on HRT” (page unavailable), the review reports six patients with a history of extensive or severe endometriosis, not seven. The same passage says 14 patients underwent surgical menopause; it does not report seven severe cases among those 14. (LLM, conf=0.88)
Checked by a reasoning model — may be wrong.
plainn = 14- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Disputed
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Therefore, optimal HRT in young women who have undergone pelvic clearance for endometriosis remains uncertain.”
§ HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey > 1. Introduction
What the sources say
- Not checked — no full text of the sourcecites [9] Hamoda, 2022, British Menopause Society tools for clinicians: Progestogens and endometrial protection, Post Reprod. Health source
- Partly supportedcites [10] Becker, 2022, ESHRE guideline: Endometriosis, Hum. Reprod. Open sourceExperimental — accuracy not yet measured
The ‘Endometriosis and menopause’ section asks whether hormone treatment is effective and safe for menopausal symptoms in women with a history of endometriosis, and the Discussion calls for more research on treatment options. Our copy does not specifically state that the optimal HRT regimen remains uncertain for young women after pelvic clearance. (LLM, conf=0.72)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: unclear — It is unclear whether it could be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“The recent guidelines of both BMS and ESHRE acknowledge the limited evidence with regard to the optimal HRT regimen in women with endometriosis.”
§ HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey > 4. Discussion > 4.5. Implications for Research
What the sources say
- Not checked — no full text of the sourcecites [9] Hamoda, 2022, British Menopause Society tools for clinicians: Progestogens and endometrial protection, Post Reprod. Health source
- Supportedcites [10] Becker, 2022, ESHRE guideline: Endometriosis, Hum. Reprod. Open source
The Results section (‘Endometriosis and menopause’; page not provided) gives a weak recommendation for combined menopausal hormone therapy, with a low evidence rating, and labels its advice on treatment after surgical menopause as good practice. The Discussion also calls for more research to clarify the most appropriate treatments. Together, these support the claim that ESHRE acknowledges limited evidence on HRT regimens; this source does not establish what the BMS guideline says. (LLM, conf=0.84)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Furthermore, the time lag (4 years) in our case between hysterectomy and the presentation with endometriosis recurrence was similar to the previously reported time (median 7.1 years) in the 14 case reports [8].”
§ HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey > 4. Discussion > 4.1. Results in the Light of Previous Research
What the sources say
- Partly supportedcites [8] Gemmell, 2017, The management of menopause in women with a history of endometriosis: A systematic review, Hum. Reprod. Update sourceExperimental — accuracy not yet measured
The Results section (‘Endometriosis recurrence in women on HRT’) reports a median of 7.1 years between surgical menopause and presentation among 14 patients, which provides a basis for comparing the citing case’s four-year interval. It does not describe 14 case reports or specifically measure time since hysterectomy; the review identified 13 reports and series covering 17 patients. (LLM, conf=0.88)
plainSingle case- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
The sources with a verdict support this claim; the rest weren’t checked yet, have no full text we could read, or their verdicts aren’t rated yet.
In the paper
“Molecular studies have revealed the overexpression of oestrogen receptor beta (ERβ), which is >100 times higher in endometriotic lesions compared to normal endometrial tissue.”
§ HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey > 4. Discussion > 4.2. Interpretation of Results
What the sources say
- Not checked — no full text of the sourcecites [14] Kitawaki, 2002, Endometriosis: The pathophysiology as an estrogen-dependent disease, J. Steroid Biochem. Mol. Biol. source
- Supportedcites [15] Bulun, 2012, Role of estrogen receptor-beta in endometriosis, Semin. Reprod. Med. source
The Abstract states that ERβ levels in endometriosis are more than 100 times higher than in endometrial tissue. The Summary likewise describes ERβ expression as possibly more than 100 times higher in endometriotic tissue than in endometrium. (LLM, conf=0.94)
boostedstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
32 more claims · 2 with their cited sources checked
Create a free account to see all 94 claims and to verify the 1 reference still open.
- Probably not a substantial claim. 22
- It may state two separate claims as one. 44
- The quote only partly states this claim. 1
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated major: it would touch a result — a value a result rests on, reported and recomputed p-values on opposite sides of the significance level, two passages that conflict with no sign which is right, or a cited work retracted before this paper was published.
In the paper
§ HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey > Abstract
“Fifty-one percent prescribe the progestogen component of C-HRT indefinitely, 22% for 3–6 months and 27% for varied durations.”
§ HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey > 3. Results > 3.2. National Survey
“A total of 60.9% of responders would give the progestogen component of HRT indefinitely, 19.3% for 1–2 years, 8.5% for 3–6 months, 5.3% for varied durations depending on severity of endometriosis, completeness of excision and patient’s age.”
Citations
Cites
ESHRE guideline: endometriosis
Becker, C. M., Bokor, A., Heikinheimo, O., Horne, A., Jansen, F., Kiesel, L., King, K., Kvaskoff, M., Nap, A., Petersen, K., et al. (2022) · Human Reproduction Open · doi:10.1093/hropen/hoac009 · Cited by 1,712 · cited 7×
“Although there is currently limited evidence for the duration of the progestogen component of HRT, both BMS and ESHRE guidelines recommend C-HRT until natural age of menopause [9.10].”
BackgroundMethodInfluentialFournier, A., Berrino, F., & Clavel-Chapelon, F. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9523-x · Cited by 693 · cited 2×
“However, current evidence suggests that the use of progesterone with oestrogen is not associated with any long-term increase in breast cancer risk, while the use of progestins carries 16–69% increased risk (depending on the type of progestin) compared with HRT never-use [16,17].”
BackgroundEndometriosis: The pathophysiology as an estrogen-dependent disease
Kitawaki, J., Kado, N., Ishihara, H., Koshiba, H., Kitaoka, Y., & Honjo, H. (2002) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/s0960-0760(02)00260-1 · Cited by 370
Surgical Treatment of Endometriosis: A 7-Year Follow-up on the Requirement for Further Surgery
Shakiba, K., Bena, J. F., McGill, K. M., Minger, J., & Falcone, T. (2008) · Obstetrics & Gynecology · doi:10.1097/aog.0b013e3181758ec6 · Cited by 339 · cited 1×
“recurrent endometriosis after TH-BSO increasing to 19% if the ovaries were conserved [6].”
BackgroundRole of Estrogen Receptor-β in Endometriosis
Bulun, S., Monsavais, D., Pavone, M., Dyson, M., Xue, Q., Attar, E., Tokunaga, H., & Su, E. (2012) · Seminars in Reproductive Medicine · doi:10.1055/s-0031-1299596 · Cited by 321 · cited 1×
“Furthermore, the highly expressed oestrogen in endometriotic tissue is present in its most biologically active form [14,15].”
BackgroundThe management of menopause in women with a history of endometriosis: A systematic review
Gemmell, L. C., Webster, K. E., Kirtley, S., Vincent, K., Zondervan, K. T., & Becker, C. M. (2017) · Human Reproduction Update · doi:10.1093/humupd/dmx011 · Cited by 154 · cited 7×
“With regard to timing of HRT after pelvic clearance with complete excision of endometriosis, limited available short-term data suggest that immediate start of HRT seems to be safe with no increased risk of endometriosis recurrence [8].”
BackgroundInfluentialAsi, N., Mohammed, K., Haydour, Q., Gionfriddo, M. R., Vargas, O. L. M., Prokop, L. J., Faubion, S. S., & Murad, M. H. (2016) · Systematic Reviews · doi:10.1186/s13643-016-0294-5 · Cited by 114
Matorras, R., Elorriaga, M. A., Pijoan, J. I., Ramón, O., & Rodrı́guez-Escudero, F. J. (2002) · Fertility and Sterility · doi:10.1016/s0015-0282(01)02981-8 · Cited by 113 · cited 1×
“5% (4/115) in women receiving combined HRT versus 0% (0/57) of women not on HRT [12].”
BackgroundRecurrence of endometriosis after hysterectomy.
(2014) · Europe PMC (PubMed Central) · Cited by 104
As‐Sanie, S., Till, S. R., Schrepf, A., Griffith, K. C., Tsodikov, A., Missmer, S. A., Clauw, D. J., & Brummett, C. M. (2021) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2021.08.038 · Cited by 100
Cited by
Cassani, C., Tedeschi, S., Cucinella, L., Morteo, V., Camnasio, C. A., Tiranini, L., Martini, E., & Nappi, R. E. (2024) · Maturitas · doi:10.1016/j.maturitas.2024.108129 · Cited by 27
Koninckx, P. R., Ussia, A., Adamyan, L. V., Wattiez, A., & Viganò, P. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14207196 · Cited by 3
“Although guidelines do not recommend HRT, two-thirds of practitioners continue to prescribe HRT, apparently without endometriosis being stimulated [83].”
Elsaadany, S., Josan, A., Crowley, R., & Gouldie, M. (2024) · Cureus · doi:10.7759/cureus.74306 · Cited by 2
“With regard to this case, risk factors for endometrial cancer included prolonged exposure to unopposed oestrogen in the context of underlying endometriosis and obesity [7].”
Endometriosis and Pelvic Pain: Understanding Medical Treatment.Preprint
Koninckx, P. R., Ussia, A., Viganò, P., Wattiez, A., & Vercellini, P. (2024) · Preprints.org · doi:10.20944/preprints202403.0500.v1 · Cited by 1
(2023) · Reactions Weekly · doi:10.1007/s40278-023-43969-2
Metadata
- Authors
- Amer, S., & Bazmi, S.
- Affiliations
- University of Nottingham (GB)
- University Hospitals of Derby and Burton NHS Foundation Trust (GB)
- Corresponding author
- Amer, Saad
- ORCID
- Amer, Saad
- Venue
- Journal of Clinical Medicine
- Publisher
- MDPI AG
- Published
- 2023-01-01
- Volume
- 12
- Issue
- 1
- Pages
- 336
- ISSN
- 2077-0383 (ISSN-L)
- PMC
- PMC9821579
- OpenAlex
- W4313472829
- Semantic Scholar
- 676084bb0c7be5167cb4b6bc3503e1d798db858b
- Cited by
- 11
- References
- 20
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 3 · 2023: 2
- FWCI
- 2.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- Journal of Clinical Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Repository@Nottingham (University of Nottingham) (publishedVersion, other-oa)
- Repository@Nottingham (University of Nottingham) (submittedVersion, cc-by)
- Topics
- Health Sciences › Medicine › Reproductive Medicine › Endometriosis Research and Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Menopause: Health Impacts and Treatments
- Health Sciences › Medicine › Obstetrics and Gynecology › Endometrial and Cervical Cancer Treatments
- Keywords
- hormone replacement therapy, endometriosis, endometriosis recurrence, chronic pelvic pain, subtotal hysterectomy, bilateral oophorectomy, endometrioma, hydronephrosis, prescribing patterns, tibolone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-02, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-02 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey. https://app.cochat.ai/papers/10.3390/jcm12010336
- The paper
- Amer, S., & Bazmi, S. (2023). HRT in Women Undergoing Pelvic Clearance for Endometriosis—A Case Report and a National Survey. Journal of Clinical Medicine. https://doi.org/10.3390/jcm12010336
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.